Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.

A patch including: a support; and an adhesive layer disposed on at least one surface of the support, in which the adhesive layer includes: at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof; a higher aliphatic alcohol; and a non-cross-linking polyvinylpyrrolidone that does not contain vinyl acetate as a constituent monomer thereof.

Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

The invention relates to a process for preparing an active-principle-containing adhesive formulation for use in a transdermal therapeutic system, comprising the following steps: a) providing an adhesive formulation containing a carboxylic acid ester-based solvent and a self-adhesive polymer matrix containing monomers of the compounds on which the polymer matrix is based, b) removing the carboxylic acid ester-based solvent and the monomers from the adhesive formulation, c) re-dissolving the compound obtained in step b) in an organic solvent that does not contain any ester groups, and adding a pharmacologically active principle having at least one hydroxyl group, carboxyl group, amino group and/or ester group so that the active-principle-containing adhesive formulation is obtained. The invention also relates to a transdermal therapeutic system containing the active-principle-containing adhesive formulation. The invention further relates to the use of said transdermal therapeutic system and to a kit containing the transdermal therapeutic system.

The present invention aims to provide a composition for promoting immunity induction and a vaccine pharmaceutical composition which are universally usable for inducing immunity to various antigens and capable of exerting a high immunity inducing effect. The present invention relates to a composition for promoting immunity induction containing at least one nuclear receptor ligand and also relates to a vaccine pharmaceutical composition for inducing immunity containing an antigen and a composition for promoting immunity induction that is at least one nuclear receptor ligand.

A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer-based layer which is remote from the skin with a rate of application of at least 80 g/m.sup.2, and an adhesive skin-contact layer which is adjacent to the polymer-based layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m.sup.2. The at least one active pharmaceutical ingredient is present in both the polymer-based layer remote from the skin and the skin-contact layer.

Compositions for the transdermal delivery of methylphenidate in a flexible, finite form are described. The compositions comprise a polymer matrix that includes methylphenidate or a pharmaceutically acceptable salt and at least one acrylic polymer that is non-reactive with methylphenidate. Methods using the compositions to achieve transdermal delivery of methylphenidate or for treating Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD), postural orthostatic tachycardia syndrome, or narcolepsy also are described.

The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof.

The present invention aims to provide an aqueous adhesive which has both good moldability and strong adhesive force to the skin, and provides good feeling when used. The present invention can provide an adhesive with good shape retention performance by formulating two or more aqueous macromolecules, polyhydric alcohols, aqueous and insoluble cross-linking agents.

Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.